Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery

PHASE3CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 30, 2021

Study Completion Date

November 30, 2021

Conditions

Heart Valve Diseases

Interventions

DRUG

Six percent hydroxy ethyl starch 130/0.4

6% HES 130/0.4 additive to ringer lactate as prime solution

DRUG

Ringer lactate

Ringer lactate as prime solution

Trial Locations (1)

Rajaie CMRC, Tehran

All Listed Sponsors

collaborator

Heart Valve Disease Research Center

UNKNOWN

lead

Rajaie Cardiovascular Medical and Research Center

OTHER

NCT05223361 - Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery | Biotech Hunter | Biotech Hunter